543434

Supriya Lifescience Ltd. submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required by Regulation 24A of SEBI (LODR) Regulations, 2015. The report, issued by M/s. DSM & Associates, confirmed that the company fully complied with all applicable SEBI regulations and Secretarial Standards, with no non-compliances or deviations observed during the review period.

Supriya Lifescience Limited announced that the audio recording of its Earnings Call, held on May 28, 2026, discussing the operational and financial performance for the quarter and year ended March 31, 2026, is now available on the company's website.

Supriya Lifescience Limited reported Q4 FY26 consolidated results: Revenue ₹276.53Cr vs ₹184.11Cr (▲50.20% YoY), EBITDA ₹97.62Cr vs ₹67.58Cr (▲44.45% YoY), PAT ₹74.23Cr vs ₹50.37Cr (▲47.37% YoY). EBITDA Margin was 35.3% vs 36.7% (▼140bps). The company delivered strong performance with revenue growth driven by the anesthetic segment and improved capacity utilization.

Supriya Lifescience Ltd. reported Standalone Revenue of ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA of ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), and PAT of ₹74.23 Cr vs ₹50.38 Cr (▲47.36% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 35.30% vs 36.71% (▼141bps). The Board recommended a final dividend of ₹1.00 per equity share (50% on face value of ₹2/- each), subject to shareholder approval.

Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.44% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.35% YoY). EBITDA Margin 35.29% vs 36.71% (▼142 bps). The board also recommended a final dividend of Re. 1.00 per equity share for the financial year ended March 31, 2026.

Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.34% YoY). EBITDA Margin 35.29% vs 36.71% (▼142bps). The company also recommended a final dividend of Re. 1.00 per equity share.